KORU Medical Systems, Inc. (NASDAQ: KRMD)

KORU Medical Systems, Inc. develops, manufactures, and commercializes innovative large-volume subcutaneous infusion solutions, primarily serving the subcutaneous drug delivery market. The company operates within the medical device industry, focusing on patient-centric solutions that facilitate the self-administration of drug therapies at home or in alternate site settings. KORU's core offerings are designed to improve the quality of life for patients with chronic illnesses, such as Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

The company generates revenue through three primary business sources: domestic core (U.S. and Canada), international core, and pharma services and clinical trials. Domestic and international core revenues stem from the sales of syringe drivers, tubing, and needles, collectively referred to as Product Revenue. These products are FDA-cleared for use with the FREEDOM Infusion Systems (FREEDOM System), which includes the FREEDOM60 Syringe Driver, FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. The primary application of these products is the delivery of subcutaneous drugs, notably immunoglobulin therapies for PIDD and CIDP. Additionally, KORU earns revenue from pharma services and clinical trials, which include Product Revenue for feasibility and clinical trials of biopharmaceutical companies, as well as non-recurring engineering services (NRE) revenues. These services are provided to biopharmaceutical companies to customize the FREEDOM System for clinical and commercial use across multiple drug categories.

• Domestic Core: This segment encompasses sales of the FREEDOM System components within the United States and Canada. The products are designed for the delivery of subcutaneous drugs, primarily immunoglobulin therapies for PIDD and CIDP. The segment caters to a market that values patient-centric, easy-to-use drug delivery solutions for home or alternate site settings.

• International Core: Similar to the domestic core, this segment involves the sale of the FREEDOM System components internationally. The products are cleared for delivery of several on-label subcutaneous indications, including Cutaquig, Cuvitru, Hizentra, Xembify, Empaveli, and Gammagard Liquid. This segment serves the global subcutaneous immunoglobulin (SCIg) market, expanding the reach of KORU's innovative drug delivery solutions beyond North America.

• Pharma Services and Clinical Trials: This segment includes Product Revenue for feasibility and clinical trials of biopharmaceutical companies, as well as NRE revenues. The services provided in this segment are crucial for biopharmaceutical companies developing new drugs, as KORU customizes the FREEDOM System for clinical and commercial use. This segment caters to the growing need for innovative drug delivery solutions in the biopharmaceutical industry.

KORU Medical Systems holds a strong position within the subcutaneous drug delivery market, particularly in the SCIg sector. The company's competitive advantages include its market-leading FREEDOM System, which is portable, easy to operate, and maintenance-free, requiring no batteries or electricity. The system operates at a lower pressure than electrical, volumetric pumps, maintaining a balance between what a patient's subcutaneous tissues can tolerate and what the system delivers. Additionally, KORU's track record of achieving regulatory clearances and successful patient use, combined with its channel access, positions the company to maximize growth in the core SCIg market and expand into new therapeutic areas.

The company's customer base primarily consists of specialty pharmacies, home infusion providers, and distributors. These entities are the primary sales contacts for KORU's products, although the company also provides education and training materials to clinicians, patients, and patient advocates both in the field and online. The FREEDOM System is sold through both direct sales and medical device distributors, with a significant portion of revenues generated through a small number of key distributors. This distribution strategy ensures that specialty pharmacy customers receive the benefit of remote inventory management and one-stop shopping.